INEGY 10 MG20 MG TABLETS

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

EZETIMIBE; SIMVASTATIN

Commercializzato da:

MERCK SHARP & DOHME ISRAEL LTD

Codice ATC:

C10AA01

Forma farmaceutica:

TABLETS

Composizione:

SIMVASTATIN 20 MG; EZETIMIBE 10 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

Gruppo terapeutico:

SIMVASTATIN

Area terapeutica:

SIMVASTATIN

Indicazioni terapeutiche:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH.Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Data dell'autorizzazione:

2012-04-30